University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 3C-19-6


An Open-Label, Multicenter, Non-Randomized, Dose-Confirmation and Cohort-Expansion Phase 1b Study to Evaluate the Safety,Tolerability, and Anti-Tumor Activity of ATP128, with or without BI 754091, in Patients with Stage IV Colorectal Cancer

Type: Treatment
Phase: Phase I
Status: Open to Accrual
Treatments: Immunotherapy, Vaccine
Randomized: Not Asked
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Heinz Josef Lenz, M.D.
Other Trial Staff:  Fahim Raian, D.M., Jiayi Jiang, D.M., Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Diana Oganyesyan, Coordinator, Janelle Luevano, Coordinator, Ramy Farag, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.